Media stories about PetIQ (NASDAQ:PETQ) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. PetIQ earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.5876309082259 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- PetIQ +25% post Q2 results; raises FY18 guidance (seekingalpha.com)
- PetIQ (PETQ) Given New $40.00 Price Target at SunTrust Banks (americanbankingnews.com)
- After-Hours Movers 08/14: (PETQ) (ATNM) (EGN) Higher; (CASA) (SBBP) (FANG) Lower (more…) (streetinsider.com)
- PetIQ beats by $0.28, beats on revenue (seekingalpha.com)
- Why PetIQ Earnings Are So Good (msn.com)
Shares of PetIQ stock traded up $2.91 during trading on Wednesday, hitting $31.19. 337,622 shares of the company were exchanged, compared to its average volume of 364,629. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.35 and a quick ratio of 1.09. PetIQ has a fifty-two week low of $17.03 and a fifty-two week high of $29.55. The company has a market capitalization of $665.34 million and a P/E ratio of 80.49.
Several brokerages have recently commented on PETQ. SunTrust Banks boosted their price target on PetIQ to $40.00 and gave the stock a “buy” rating in a research note on Wednesday. ValuEngine raised PetIQ from a “hold” rating to a “buy” rating in a research note on Thursday, July 12th. Jefferies Financial Group boosted their price target on PetIQ from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, July 2nd. Zacks Investment Research raised PetIQ from a “sell” rating to a “hold” rating in a research note on Wednesday, April 18th. Finally, BidaskClub lowered PetIQ from a “hold” rating to a “sell” rating in a research note on Friday, May 4th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $30.33.
In related news, CFO John Newland sold 5,500 shares of PetIQ stock in a transaction that occurred on Thursday, June 21st. The stock was sold at an average price of $24.53, for a total transaction of $134,915.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Mccord Christensen sold 13,652 shares of PetIQ stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $23.00, for a total value of $313,996.00. The disclosure for this sale can be found here. Insiders have sold a total of 102,000 shares of company stock valued at $2,611,093 over the last 90 days. Insiders own 45.26% of the company’s stock.
PetIQ Company Profile
PetIQ, Inc develops, manufactures, and distributes pet medications, and health and wellness products for dogs and cats in the United States, Canada, and Europe. It offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.
Recommended Story: Marijuana Stocks Investing Considerations
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.